Salbutamol sulfate inhalation aerosol is a selective β?-adrenergic receptor agonist. Its primary mechanism involves binding to β?-receptors located on bronchial smooth muscle cells. Activation of these receptors leads to increased production of cyclic adenosine monophosphate (cAMP), which subsequently reduces intracellular calcium levels. This results in the relaxation of smooth muscles and bronchodilation, thereby alleviating symptoms of bronchial spasms. Additionally, salbutamol inhibits the release of inflammatory mediators from mast cells and other sensitized cells, further reducing bronchial spasms.
Salbutamol sulfate inhalation aerosol is widely used in the treatment of respiratory conditions characterized by bronchial spasms. Its primary applications include:
The future outlook for salbutamol sulfate inhalation aerosol is promising due to its proven efficacy and safety profile. Ongoing research is exploring its potential in combination therapies for more effective management of respiratory diseases. Additionally, advancements in inhaler technology are aimed at improving drug delivery and patient compliance. The increasing prevalence of asthma and COPD, particularly in developing countries, is expected to drive the demand for this medication.
Adults:
Salbutamol sulfate inhalation aerosol should be stored at temperatures below 30°C (86°F), protected from light and extreme cold. The canister should not be punctured, broken, or burned, even if it appears empty. It is also important to keep the inhaler out of reach of children.
智藥研習社官方微信
制藥在線(xiàn)官方微信
2006-2025 上海博華國際展覽有限公司版權所有（保留一切權利）
滬ICP備05034851號-57
